WAVEMAN · COMPANY

RCEL · Avita Medical, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

RCEL

Name: AVITA Medical, Inc. (RCEL) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

AVITA Medical, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001762303

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$222.1K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+10.9%

XBRL, annual

NET MARGIN

-68.5%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$222.1K over 180 days

+$70.6K over 90 days

more than 84% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

43 funds added or opened last quarter

below 65% of Medical Devices

REVENUE

+10.9% year over year

more than 57% of Medical Devices

MARGIN

-68.5% net margin

below 79% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

43 funds added or opened positions in the latest 13F quarter, of 74 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +150.8%

+150.8%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $222.1K bought by insiders over 180 days, 43 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, AVITA Medical, Inc. insiders bought a net $222.1K of stock across 53 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

O'Toole David D

CFO

BUY

2026-06-12

2,000.0

$7.9K

Woody Joseph Fralin

Director

BUY

2026-06-09

5,200.0

$20.8K

Woody Joseph Fralin

Director

BUY

2026-06-09

5,000.0

$20.9K

Woody Joseph Fralin

Director

BUY

2026-06-09

5,000.0

$21.0K

Woody Joseph Fralin

Director

BUY

2026-06-03

5,000.0

$20.4K

53 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 48 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

VANGUARD CAPITAL MANAGEMENT LLC

1,333,914.0 sh

$5.5M

BlackRock, Inc.

564,952.0 sh

$2.3M

GEODE CAPITAL MANAGEMENT, LLC

339,822.0 sh

$1.4M

MARSHALL WACE, LLP

338,387.0 sh

$1.4M

AQR CAPITAL MANAGEMENT LLC

321,013.0 sh

$1.3M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Ultra-Small Company Fund

$112.5K POSITION · AS OF 2026-03-31

0.1%

Small Cap Core Fund

$41.5K POSITION · AS OF 2026-03-31

0.0%

iShares Micro-Cap ETF

$132.1K POSITION · AS OF 2026-03-31

0.0%

Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF

$91.7K POSITION · AS OF 2026-02-28

0.0%

1290 VT Micro Cap Portfolio

$8.6K POSITION · AS OF 2026-03-31

0.0%

PD Small-Cap Growth Index Portfolio

$5.1K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 11 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$70.9M	$63.9M	$50.1M	$34.4M
GROSS PROFIT	$58.8M	$55.2M	$42.4M	$28.4M
OPERATING INCOME	$-42.5M	$-56.6M	$-42.7M	$-27.5M
NET INCOME	$-48.6M	$-61.8M	$-35.4M	$-26.7M
EPS (DILUTED)	-1.74	-2.39	-1.40	1.07
OPERATING CASH FLOW	$-31.2M	$-48.9M	$-38.0M	$-19.1M
CASH	$10.2M	$14.1M	$22.1M	$18.2M
LONG-TERM DEBT	$0	$42.2M	$39.8M	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE